Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Share :
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 23 Sep 2021
Views: 2289
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Prof Sanjay Popat speaks to ecancer about the challenges in first line ALK positive NSCLC management and the emerging data on ALK TKIs in ALK positive NSCLC from ESMO and WCLC 2021.

Initially, he shares his expert opinion on the latest data and discussions from WCLC and ESMO 2021 regarding ALK positive NSCLC. Prof Popat then discusses the challenges associated with 1L ALK positive NSCLC management. He talks about the ALTA-1L final analysis, phase III CROWN study and BrigALK2 study.

Prof Popat also mentions the unique efficacy of ensartinib on different ALK fusion subtypes evaluated by plasma ctDNA. He concludes by talking about what the future looks like for the treatment of ALK positive NSCLC.

ALTA-1L Trial
CROWN study
BrigALK2 study
Efficacy of Ensartinib on Different ALK Fusion Subtypes Evaluated by Plasma ctDNA
Challenges regarding 1L ALK+ NSCLC management
Future treatment of ALK+ NSCLC

ecancer's filming has been kindly supported by Takeda through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.